| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Ritonavir Posaconazole 1063 | Green: Administer standard doses | Administer standard doses | Potential increased ritonavir effects |
Ritonavir AUC increased 80%; Cmax increased 49% |
400 mg BID | ||
| Darunavir Posaconazole 997 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Potential for increased risk of darunavir and posaconazole adverse effects |
Dose adjustment not established, monitor for increased DRV and / or antifungal adverse reactions |
|||
| Atazanavir Posaconazole 805 | Green: Administer standard doses | Administer standard doses | Potential for increased atazanavir adverse effects |
Atazanavir AUC increased 268%, Cmax increased 155% |
400 mg BID | Monitor closely for atazanavir adverse effects during coadministration |
|
| Atazanavir Posaconazole 804 | Green: Administer standard doses | Administer standard doses | Potential for increased atazanavir adverse effects |
Atazanavir AUC increased 146%, Cmax increased 53% |
400 mg BID | Monitor closely for atazanavir adverse effects during coadministration |
|
| Etravirine Posaconazole 521 | Green: Administer standard doses | Administer standard doses | Not studied (may increase etravirine levels) |
Not studied |
Monitor for etravirine related toxicities |
||
| Efavirenz Posaconazole 492 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Decreased posaconazole effects |
400 mg BID x 10 and 20 days | Posaconazole AUC decreased 50%; Cmax decreased 45% |
Consider using alternative agents. If coadministering, dose adjustment has not been established |
|
| Efavirenz Posaconazole 491 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Decreased posaconazole effects |
No significant change |
400 mg BID for 10 and 20 days | Posaconazole AUC decreased 50%; Cmax decreased 45% |
Consider using alternative agents. If coadministering, dose adjustment has not been established |
| Efavirenz Posaconazole 490 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: risks likely to outweigh benefits | Decreased posaconazole effects |
No significant change |
400 mg BID | Posaconazole AUC decreased 50%; Cmax decreased 45% |
Consider using alternative agents. If coadministering, dose adjustment has not been established |
| Elvitegravir Posaconazole 273 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, monitor posaconazole concentrations. |
||||
| Maraviroc Posaconazole 52 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of maraviroc | Potential maraviroc-associated adverse effects |
Reduce maraviroc dose to 150 mg BID |
